SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

In October, the FDA removed Mounjaro and Zepbound—the diabetes and obesity GLP-1 drugs made by Eli Lilly—from the shortage ...

Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...

Eli Lilly' s blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the ...

Another issue for investors is that Eli Lilly adjusted its guidance for the year, now projecting its adjusted EPS to fall ...

Rather than bribing and wheedling physicians to pretty-please-prescribe-our-drug, websites allow companies to deal drugs ...

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

Lilly CEO Dave Ricks in Wednesday’s third-quarter earnings call acknowledged that the company is at the mercy of wholesaler ...

Eli Lilly CEO David Ricks told investors this week that the sale of cheaper, knockoff versions of the company’s blockbuster ...

Sales of Eli Lilly’s (LLY) blockbuster weight loss drug Zepbound are still booming, but just not at the level Wall Street was ...